TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01303549
Drug: Anidulafungin
Normalized name: Anidulafungin
DrugBank: Anidulafungin (DB00362)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.
Study: NCT01303549
Drug: Liposomal amphotericin B
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.
Study: NCT04302896
Drug: lamivudine oral tablet 300mg
Normalized name: lamivudine Oral Tablet
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine (Epivir®, 3TC) is a nucleoside analogue reverse transcriptase inhibitor FDA-approved in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients at least 3 months of age. Lamivudine 300mg tablets \[Apotex Inc.\] are gray, modified diamond-shaped, film-coated, and engraved with LMV 300 on one side and APO on the reverse side. Inactive ingredients are black iron oxide, colloidal silicon dioxide, crospovidone, hydroxypropyl cellulose, hydroxypropyl methylcellulose, lactose anhydrous, magnesium stearate, polyethylene glycol, and titanium dioxide.
Study: NCT04406376
Drug: Prednisone tablet
Normalized name: Prednisone Tablets
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment of Bell's Palsy with prednisone, with or without tapering down.
Study: NCT02155465
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib 10mg PO BID~Ruxolitinib 15mg PO BID~Ruxolitinib 20mg PO BID
Study: NCT02155465
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erlotinib 150mg PO QD
Study: NCT03586726
Drug: Balovaptan
Normalized name: Balovaptan
DrugBank: Balovaptan (DB14823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Period 1, balovaptan was administered alone as a once daily (qd) dose on Days 1 to 10.~In Period 2, balovaptan was administered as a qd dose on Days 7 to 16.
Study: NCT03586726
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Period 2, 600 mg of rifampicin will be administered alone as a qd dose from Day 1 to Day 6, and as a qd dose on Days 7 to 16.
Study: NCT00980538
Drug: Etravirine
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be dosed with etravirine by weight up to a maximum dose of 200 mg bid until switched to an etravirine-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
Study: NCT01711554
Drug: Isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01711554
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01165905
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
Study: NCT00627419
Drug: IPI-504
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
Study: NCT00000194
Drug: Cycloserine
Normalized name: Cycloserine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03707808
Drug: intratumoral injection of autologous CD1c (BDCA-1)+ myDC
Normalized name: sodium bicarbonate Injection [Neut brand of sodium bicarbonate]
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intratumoral injections plus intravenous administration
Study: NCT03707808
Drug: Intratumoral injection of ipilimumab and AS01b
Normalized name: ipilimumab Injection
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intratumoral injection of ipilimumab and AS01b
Study: NCT03707808
Drug: IV nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab administered intravenously
Study: NCT04432285
Drug: Botulinum toxin
Normalized name: Botulinum toxin
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated intramuscular injections at regular intervals of around 3 months
Study: NCT01970215
Drug: TA-8995
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01970215
Drug: Atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01970215
Drug: TA-8995 0mg (placebo)
Normalized name: Ta
DrugBank: Tantalum (DB12859)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00999791
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02499328
Drug: tremelimumab (treme)
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tremelimumab
Study: NCT04477291
Drug: CG-806
Normalized name: Alkamide 101-cg
DrugBank: Coco diethanolamide (DB18828)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.
Study: NCT03938246
Drug: TVB-2640 25 mg (US)
Normalized name: podophyllin
DrugBank: Podophyllin (DB09094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, tablet, daily dosing
Study: NCT03938246
Drug: TVB-2640 50 mg (China)
Normalized name: China-Gel
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, tablet, daily dosing
Study: NCT03938246
Drug: Placebo (China)
Normalized name: China-Gel
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose, tablet, daily dosing
Study: NCT00415363
Drug: enzastaurin
Normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1125 mg loading dose then 500 mg, oral, daily, until disease progression
Study: NCT01975688
Drug: Sativex
Normalized name: Castanea sative leaf extract
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.~Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD.
Study: NCT04451772
Drug: Elsubrutinib
Normalized name: Elsubrutinib
DrugBank: Elsubrutinib (DB18850)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; Oral
Study: NCT04451772
Drug: Placebo for Elsubrutinib
DrugBank: Rutin (DB01698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule; Oral
Study: NCT04451772
Drug: Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Film-coated tablet; Oral
Study: NCT04451772
Drug: Placebo for Upadacitinib
Normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Film-coated tablet; Oral
Study: NCT00708448
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 150 mg/day
Study: NCT04673591
Drug: Tregalizumab
Normalized name: Tregalizumab
DrugBank: Tregalizumab (DB13073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a monoclonal antibody designed for the treatment of allergic asthma indication
Study: NCT00708448
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15mg/kg q 21 days
Study: NCT03061734
Drug: Naltrexone Alone (regular dose)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone Alone plus Placebo
Study: NCT02335658
Drug: DSP-5423P
Normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40-80mg/day
Study: NCT03834883
Drug: Progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
Study: NCT03834883
Drug: Ibutilide
Normalized name: Ibutilide
DrugBank: Ibutilide (DB00308)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
Study: NCT05122208
Drug: Famotidine Tablets
Normalized name: Famotidine Tablets
DrugBank: Famotidine (DB00927)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 160 mg/day Famotidine
Study: NCT01661855
Drug: Riluzole
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
Study: NCT02801656
Drug: Vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vancomycin po 125 mg qid x 10 days
Study: NCT02801656
Drug: Vancomycin Placebo
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Matching placebo to Vancomycin
Study: NCT01886573
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given SC
Study: NCT01886573
Drug: Entinostat
Normalized name: entinostat
DrugBank: Entinostat (DB11841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00829179
Drug: RhuMab-E25
Normalized name: RHUMAB-E25
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.
Study: NCT00737191
Drug: olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT04134182
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 mg/kg intravenously every 2 weeks during 16 weeks
Study: NCT04134182
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1 mg/kg intravenously every 3 weeks for four doses
Study: NCT00247975
Drug: L-carnitine
Normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be randomized to L-carnitine therapy or placebo. Patients in the treatment group will receive oral L-carnitine (3 grams daily) for 3 days prior to chemotherapy, 1 gram of intravenous L-carnitine (5 cc over 5 minutes, prior to chemotherapy) on the day of chemotherapy and oral L-carnitine (3 grams daily) for 3 days after chemotherapy.
Study: NCT00217048
Drug: Yohimbine, oral
DrugBank: Yohimbine (DB01392)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01736059
Drug: CD34+ bone marrow stem cells intravitreal
Normalized name: Bone-marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02409849
Drug: Octreotide lar
Normalized name: octreotide LAR 20 MG Injection
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02197247
Drug: Rifampicin
Normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
Study: NCT00068744
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00068744
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02456935
Drug: Esomeprazole 40 mg QD
Normalized name: esomeprazole 40 MG
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.
Study: NCT02053116
Drug: PF-05175157
Normalized name: PF-05175157
DrugBank: PF-05175157 (DB12096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 200 mg, twice daily, 6 weeks
Study: NCT01850628
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01821612
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01821612
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01821612
Drug: 5-fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT01821612
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV
Study: NCT03330847
Drug: Olaparib Continuous (28-Day cycle) 300 mg BD.
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).
Study: NCT03330847
Drug: Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.
Study: NCT03330847
Drug: Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.
Study: NCT03278379
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
Study: NCT00360087
Drug: Bosentan
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02140060
Drug: Dose Level B / Brinzolamide 1% ophthalmic suspension
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed combination
Study: NCT02140060
Drug: Dose Level C / Brinzolamide 1% ophthalmic suspension
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fixed combination
Study: NCT02140060
Drug: Brinzolamide 1% ophthalmic suspension AZOPT®
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02140060
Drug: Travoprost 0.004% ophthalmic solution TRAVATAN Z®
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02140060
Drug: Travoprost solution vehicle
Normalized name: travoprost Ophthalmic Solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inactive ingredients used for masking purposes
Study: NCT02140060
Drug: Brinzolamide suspension vehicle
Normalized name: brinzolamide Ophthalmic Suspension
DrugBank: Brinzolamide (DB01194)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Inactive ingredients used for masking purposes
Study: NCT00544882
Drug: DR-1021
Normalized name: Dr. Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
Study: NCT00637897
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00637897
Drug: ixabepilone
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00637897
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00637897
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Normalized name: Albumin-stabilized nanoparticle (130 nm)
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00637897
Drug: paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02756897
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT02756897
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01316549
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given as injection
Study: NCT00060918
Drug: carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00060918
Drug: metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04041843
Drug: Apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban 10 mg twice daily p.o. for seven days followed by 5 mg twice daily p.o. for children and adolescents weighting ≥40 kg
Study: NCT03363503
Drug: Salmeterol/Fluticasone Capsair®
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Capsair® for 8 weeks
Study: NCT03363503
Drug: Salmeterol/Fluticasone Diskus®
DrugBank: Salmeterol (DB00938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Salmeterol/Fluticasone 50/500 mcg Inhalation Powder (1 puff) twice daily (approximately every 12 hr) via Diskus® for 8 weeks
Study: NCT00161564
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03762564
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8 mg/kg i.v. infusion on day 1 and 15
Study: NCT04374136
Drug: AL001
Normalized name: AL001
DrugBank: Latozinemab (DB16978)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intravenous (IV) infusion
Study: NCT04374136
Drug: Open label - AL001
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via intravenous (IV) infusion
Study: NCT03762564
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 80 mg/m2 on day 1, 8, 15
Study: NCT03318471
Drug: MgSo4
Normalized name: MgSO4
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes
Study: NCT00479258
Drug: Subcutaneous Insulin (subject's prescribed)
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous insulin with dose adjusted according to premeal blood glucose
Study: NCT02985593
Drug: KHK4083
Normalized name: Anti-CD134 human monoclonal antibody (IgG1, KHK4083 dimer)
DrugBank: Rocatinlimab (DB18809)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01895842
Drug: Ruxolitinib
Normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.~Starting dose level for Part 2: Maximum tolerated dose from Part 1.
Study: NCT03932162
Drug: Insulin-Like Growth Factor 1
Normalized name: INSULIN-LIKE GROWTH FACTOR 1
DrugBank: Mecasermin (DB01277)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Growth factor protein
Study: NCT00005877
Drug: rubitecan
Normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01825447
Drug: Oxycodone + Naltrexone
Normalized name: naltrexone / oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
Study: NCT01825447
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
Study: NCT03004105
Drug: Selumetinib
Normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle~Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.~Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in.
Study: NCT03004105
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
Study: NCT02663453
Drug: multicomponent lipid emulsion
Normalized name: propofol lipid emulsion
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
Study: NCT02663453
Drug: pure soybean oil lipid emulsion
Normalized name: propofol lipid emulsion
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
Study: NCT00871182
Drug: Tiotropium Handihaler
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose, tiotropium 18 mcg administered via the Handihaler
Study: NCT04998838
Drug: Tenofovir Disoproxil Fumarate 300 mg daily; HBV birth dose vaccine; hepatitis B immune globulin (HBIG)
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antenatal screening for HBV, anti-viral treatment with tenofovir according to treatment eligibility criteria, and birth dose vaccination at delivery to prevent mother-to-child transmission of HBV
Study: NCT00468520
Drug: low dose oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no